Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BALANCE: Ipragliflozin (ASP1941) + Metformin in T2DM
NCT01117584Phase 2Completed
- Sponsor
- Astellas Pharma
- Start
- Apr 2010
- Primary completion
- Apr 2011
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial of ipragliflozin in type 2 diabetes mellitus (T2DM) (5 arms), sponsored by Astellas Pharma. Primary endpoint: Change from baseline in HbA1c at 12 weeks. Started Apr 2010; status: completed.
02
Drugs
ipragliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01117584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01117584.